Astym® therapy: a systematic review
- PMID: 30963065
- PMCID: PMC6409241
- DOI: 10.21037/atm.2018.11.49
Astym® therapy: a systematic review
Abstract
Soft tissue dysfunction can result from the degeneration of tissues as in the case of degenerative tendinopathy or from the build-up of problematic scar tissue, which can be the result of several aggravating factors, including overuse injuries, acute or chronic trauma, or as a result of surgery. This dysfunction often results in impaired movement, pain, and swelling of the affected area, which can lead to patient dissatisfaction and a lower quality of life. These soft tissue dysfunctions also have a marked economic impact. Although a number of traditional treatments attempt to address these issues, no optimal treatment choice has emerged. Traditional treatments are not always successful, can be invasive, and can consume many medical resources. A relatively new treatment approach, Astym therapy, is a potentially useful, non-invasive, more cost-effective option. This therapy was developed to address soft-tissue dysfunctions by stimulating the regeneration of soft tissues and the resorption of inappropriate scar tissue/fibrosis. It has been reported to help with the resorption and remodeling of abnormal tissue, thereby leading to improved motion, function and pain relief. The purpose of this analysis was to review the published literature related to Astym therapy on various musculoskeletal disorders. Specifically, we evaluated the effectiveness of this therapeutic method on disorders related to the: (I) knee; (II) upper extremity; (III) hamstring muscles; and (IV) ankle and Achilles tendon injuries.
Keywords: Soft tissue injuries; regeneration; regenerative therapy; tissue remodeling.
Conflict of interest statement
Conflicts of Interest: The study was sponsored by Performance Dynamics, Inc. M Chughtai is paid consultant of Cymedica, DJ Orthopaedics, Peerwell, Performance Dynamics Inc., Reflection, Sage Products, Stryker. A Bhave: stock or stock options of Amgen Co., Cymedica Otrhopedics, Peerwell, and Pfizer; paid consultant of Cymedica Orthopedics, DJ Orthopaedics, On Going Care, and Stryker; IP royalties of Guardian Inc.; Editorial or governing board of Journal of Society of Indian Physiotherapists. MA Mont: Board or committee member of AAOS; paid consultant of Abbott, Cymedica, Mallinckrodt Pharmaceuticals, Pacira, Performance Dynamics Inc., Sage; paid consultant and research support of DJ Orthopaedics, Johnson & Johnson, Ongoing Care Solutions, Orthosensor, TissueGene; editorial or governing board of Journal of Arthroplasty, Journal of Knee Surgery; IP royalties of Microport; research support of National Institutes of Health (NIAMS & NICHD); editorial or governing board of Orthopedics, Surgical Techniques International; stock or stock options of Peerwell; IP royalties, paid consultant and research support of Stryker.
References
Publication types
LinkOut - more resources
Full Text Sources